PhaseBio Pharmaceuticals Inc. — CureCurrent

How to interpret these research links

Connected source records

The exact organization name PhaseBio Pharmaceuticals Inc. appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13

Recruiting shown0

Roles1

SourceClinicalTrials.gov

Clinical trials

13 shown

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).NCT04433546 · lead sponsor · 2020-07-15

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004NCT03795428 · lead sponsor · 2019-04-10

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAHNCT03556020 · lead sponsor · 2018-07-15

A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAHNCT03315507 · lead sponsor · 2017-10-20

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEFNCT02808585 · lead sponsor · 2016-06-01

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DMNCT02581657 · lead sponsor · 2015-10-01

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential HypertensionNCT01873885 · lead sponsor · 2013-06-01

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes MellitusNCT01835730 · lead sponsor · 2013-04-01

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DMNCT01658501 · lead sponsor · 2012-07-01

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes MellitusNCT01427257 · lead sponsor · 2012-02-01

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential HypertensionNCT01523067 · lead sponsor · 2012-01-01

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal FunctionNCT01478399 · lead sponsor · 2011-12-01

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes MellitusNCT01236404 · lead sponsor · 2010-11-01

Drugs studied in this sponsor's trials

2 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing PhaseBio Pharmaceuticals Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

metformin1

placebo1

metformin RxCUI 6809 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.